- Home
- APGE vs ZLAB Comparison
APGE vs ZLAB Comparison
Compare APGE & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APGE
- ZLAB
- Stock Information
- Founded
- APGE 2022
- ZLAB 2013
- Country
- APGE United States
- ZLAB China
- Employees
- APGE N/A
- ZLAB N/A
- Industry
- APGE Biotechnology: Biological Products (No Diagnostic Substances)
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- APGE Health Care
- ZLAB Health Care
- Exchange
- APGE Nasdaq
- ZLAB Nasdaq
- Market Cap
- APGE 3.0B
- ZLAB 3.0B
- IPO Year
- APGE 2023
- ZLAB 2017
- Fundamental
- Price
- APGE $48.46
- ZLAB $26.67
- Analyst Decision
- APGE Strong Buy
- ZLAB Strong Buy
- Analyst Count
- APGE 6
- ZLAB 4
- Target Price
- APGE $75.40
- ZLAB $52.50
- AVG Volume (30 Days)
- APGE 588.6K
- ZLAB 960.6K
- Earning Date
- APGE 11-12-2024
- ZLAB 11-12-2024
- Dividend Yield
- APGE N/A
- ZLAB N/A
- EPS Growth
- APGE N/A
- ZLAB N/A
- EPS
- APGE N/A
- ZLAB N/A
- Revenue
- APGE N/A
- ZLAB $355,748,000.00
- Revenue This Year
- APGE N/A
- ZLAB $48.50
- Revenue Next Year
- APGE N/A
- ZLAB $47.37
- P/E Ratio
- APGE N/A
- ZLAB N/A
- Revenue Growth
- APGE N/A
- ZLAB 35.01
- 52 Week Low
- APGE $22.20
- ZLAB $13.48
- 52 Week High
- APGE $72.29
- ZLAB $36.60
- Technical
- Relative Strength Index (RSI)
- APGE 47.85
- ZLAB 45.71
- Support Level
- APGE $41.85
- ZLAB $25.85
- Resistance Level
- APGE $48.27
- ZLAB $29.87
- Average True Range (ATR)
- APGE 3.56
- ZLAB 1.05
- MACD
- APGE 0.31
- ZLAB -0.18
- Stochastic Oscillator
- APGE 47.51
- ZLAB 21.98
About APGE Apogee Therapeutics Inc.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Its two programs are APG777 and APG808, which initially develop for treating AD and COPD, respectively.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.